Heike E Daldrup-Link

List of Publications by Year in Descending Order

300 papers	9,604 citations	52 h-index	91 g-index
334 ext. papers	10,978 ext. citations	7 avg, IF	6.03 L-index

#	Paper	IF	Citations
300	In vivo imaging of nanoparticle-labeled CAR T cells.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	5
299	Disparate participation by gender of conference attendants in scientific discussions.. *PLoS ONE*, **2022**, 17, e0262639	3.7	0
298	Diagnostic Accuracy of 2-[F]FDG-PET and whole-body DW-MRI for the detection of bone marrow metastases in children and young adults.. *European Radiology*, **2022**, 1	8	1
297	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.. *Nature Medicine*, **2022**,	50.5	6
296	Pediatric PET/MRI Neuroimaging: Overview **2022**, 737-740		
295	Artificial intelligence for bone cancer imaging **2022**, 75-90		
294	Mechanoporation enables rapid and efficient radiolabeling of stem cells for PET imaging.. *Scientific Reports*, **2022**, 12, 2955	4.9	
293	Web-Based Application for Biomedical Image Registry, Analysis, and Translation (BiRAT). *Tomography*, **2022**, 8, 1453-1462	3.1	0
292	In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma. *Molecular Imaging and Biology*, **2021**, 1	3.8	0
291	Validation of Deep Learning-based Augmentation for Reduced F-FDG Dose for PET/MRI in Children and Young Adults with Lymphoma. *Radiology: Artificial Intelligence*, **2021**, 3, e200232	8.7	0
290	Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. *Molecular Imaging and Biology*, **2021**, 23, 625-638	3.8	2
289	One-stop local and whole-body staging of children with cancer. *Pediatric Radiology*, **2021**, 1	2.8	0
288	Challenges and Initiatives in Diversity, Equity and Inclusion in Cancer Molecular Imaging. *Frontiers in Oncology*, **2021**, 11, 638692	5.3	1
287	Ascorbic Acid and Iron Supplement Treatment Improves Stem Cell-Mediated Cartilage Regeneration in a Minipig Model. *American Journal of Sports Medicine*, **2021**, 49, 1861-1870	6.8	3
286	How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol. *Pediatric Radiology*, **2021**, 1	2.8	3
285	Clinical impact of PET/MRI in oligometastatic colorectal cancer. *British Journal of Cancer*, **2021**, 125, 975-982	8.7	3
284	Pediatric Molecular Imaging **2021**, 1131-1147		

283	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1522-1537	8.8	3
282	Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2771-2781	8.8	12
281	The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine. *Advanced Drug Delivery Reviews*, **2021**, 174, 337-347	18.5	9
280	Ferumoxytol magnetic resonance imaging detects joint and pleural infiltration of bone sarcomas in pediatric and young adult patients. *Pediatric Radiology*, **2021**, 51, 2521-2529	2.8	0
279	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. *Molecular Cancer Therapeutics*, **2021**, 20, 2016-2025	6.1	1
278	Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. *Pharmacological Research*, **2021**, 171, 105780	10.2	37
277	PET/MRI Improves Management of Children with Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 1334-1340	8.9	2
276	Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study. *Biointerphases*, **2021**, 16, 011008	1.8	3
275	Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. *Radiology*, **2020**, 296, 143-151	20.5	13
274	Instant labeling of therapeutic cells for multimodality imaging. *Theranostics*, **2020**, 10, 6024-6034	12.1	7
273	Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. *Theranostics*, **2020**, 10, 3612-3621	12.1	14
272	Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains. *Nanotheranostics*, **2020**, 4, 195-200	5.6	4
271	Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. *European Radiology*, **2020**, 30, 1790-1803	8	11
270	Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans. *Molecular Imaging and Biology*, **2020**, 22, 722-729	3.8	6
269	GdVO:Eu,Bi Nanoparticles as a Contrast Agent for MRI and Luminescence Bioimaging. *ACS Omega*, **2019**, 4, 15806-15814	3.9	10
268	Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. *Cephalalgia*, **2019**, 39, 1407-1420	6.1	11
267	Tracking Stem Cell Implants in Cartilage Defects of Minipigs by Using Ferumoxytol-enhanced MRI. *Radiology*, **2019**, 292, 129-137	20.5	16
266	Magnetic resonance imaging of stem cell-macrophage interactions with ferumoxytol and ferumoxytol-derived nanoparticles. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2019**, 11, e1552	9.2	6

265	Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma. *Cell Death and Disease*, **2019**, 10, 36	9.8	43
264	Tumor Formation of Adult Stem Cell Transplants in Rodent Arthritic Joints. *Molecular Imaging and Biology*, **2019**, 21, 95-104	3.8	3
263	Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on. *Molecular Oncology*, **2019**, 13, 2049-2061	7.9	16
262	Pediatric Molecular Imaging. *Pediatric Oncology*, **2019**, 347-367	0.5	
261	Artificial intelligence applications for pediatric oncology imaging. *Pediatric Radiology*, **2019**, 49, 1384-1392	2.8	16
260	The yin and yang of imaging tumor associated macrophages with PET and MRI. *Theranostics*, **2019**, 9, 7730-7748	12.1	33
259	How to Prevent a Leaky Pipeline in Academic Radiology: Insights From a Faculty Survey. *Journal of the American College of Radiology*, **2019**, 16, 1220-1224	3.5	2
258	Theranostic nanoparticles enhance the response of glioblastomas to radiation. *Nanotheranostics*, **2019**, 3, 299-310	5.6	9
257	Cover Image, Volume 11, Issue 4. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2019**, 11, e1572	9.2	
256	Variability in billing practices for whole-body magnetic resonance imaging: reply to Degnan et al. *Pediatric Radiology*, **2019**, 49, 154	2.8	1
255	Ferumoxytol Can Be Used for Quantitative Magnetic Particle Imaging of Transplanted Stem Cells. *Molecular Imaging and Biology*, **2019**, 21, 465-472	3.8	35
254	Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study. *Radiology*, **2019**, 290, 198-206	20.5	36
253	Association of Tumor [F]FDG Activity and Diffusion Restriction with Clinical Outcomes of Rhabdomyosarcomas. *Molecular Imaging and Biology*, **2019**, 21, 591-598	3.8	7
252	Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. *Neurosurgery*, **2018**, 82, 770-780	3.2	25
251	Bone marrow oedema predicts bone collapse in paediatric and adolescent leukaemia patients with corticosteroid-induced osteonecrosis. *European Radiology*, **2018**, 28, 410-417	8	10
250	Current utilization and procedural practices in pediatric whole-body MRI. *Pediatric Radiology*, **2018**, 48, 1101-1107	2.8	25
249	Ferumoxytol Is Not Retained in Kidney Allografts in Patients Undergoing Acute Rejection. *Molecular Imaging and Biology*, **2018**, 20, 139-149	3.8	10
248	Transfer learning on fused multiparametric MR images for classifying histopathological subtypes of rhabdomyosarcoma. *Computerized Medical Imaging and Graphics*, **2018**, 65, 167-175	7.6	36

247	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. *Molecular Imaging and Biology*, **2018**, 20, 324-335	3.8	22
246	The Protein Corona around Nanoparticles Facilitates Stem Cell Labeling for Clinical MR Imaging. *Radiology*, **2018**, 286, 938-947	20.5	22
245	Ferumoxytol-based Dual-modality Imaging Probe for Detection of Stem Cell Transplant Rejection. *Nanotheranostics*, **2018**, 2, 306-319	5.6	7
244	Photoacoustic Imaging of Embryonic Stem Cell-Derived Cardiomyocytes in Living Hearts with Ultrasensitive Semiconducting Polymer Nanoparticles. *Advanced Functional Materials*, **2018**, 28, 1704939	15.6	51
243	Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients. *Clinical Cancer Research*, **2018**, 24, 6223-6229	12.9	15
242	Clinical Tracking of Cell Transfer and Cell Transplantation: Trials and Tribulations. *Radiology*, **2018**, 289, 604-615	20.5	60
241	Writing a review article - Are you making these mistakes?. *Nanotheranostics*, **2018**, 2, 197-200	5.6	7
240	Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. *Clinical Cancer Research*, **2018**, 24, 4110-4118	12.9	60
239	Detection of Stem Cell Transplant Rejection with Ferumoxytol MR Imaging: Correlation of MR Imaging Findings with Those at Intravital Microscopy. *Radiology*, **2017**, 284, 495-507	20.5	19
238	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. *Kidney International*, **2017**, 92, 47-66	9.9	168
237	Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics. *Drug Discovery Today*, **2017**, 22, 1421-1429	8.8	80
236	The Fermi Paradox in STEM-Where Are the Women Leaders?. *Molecular Imaging and Biology*, **2017**, 19, 807-809	3.8	5
235	Ten Things You Might Not Know about Iron Oxide Nanoparticles. *Radiology*, **2017**, 284, 616-629	20.5	99
234	Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. *Molecular Imaging*, **2017**, 16, 1536012117730950	3.7	4
233	A PET/MR Imaging Approach for the Integrated Assessment of Chemotherapy-induced Brain, Heart, and Bone Injuries in Pediatric Cancer Survivors: A Pilot Study. *Radiology*, **2017**, 285, 971-979	20.5	6
232	How PET/MR Can Add Value For Children With Cancer. *Current Radiology Reports*, **2017**, 5, 1	0.5	14
231	A Novel Theranostic Strategy for -Expressing Glioblastomas Impacts Survival. *Molecular Cancer Therapeutics*, **2017**, 16, 1909-1921	6.1	28
230	Whole-body PET/MRI of Pediatric Patients: The Details That Matter. *Journal of Visualized Experiments*, **2017**,	1.6	2

229	Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?. *Journal of Nuclear Medicine*, **2016**, 57, 70-7	8.9	12
228	Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. *JCI Insight*, **2016**, 1,	9.9	10
227	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. *Lancet Oncology, The*, **2016**, 17, 1396-1408	21.7	253
226	Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects. *Scientific Reports*, **2016**, 6, 25897	4.9	15
225	Speeding up PET/MR for cancer staging of children and young adults. *European Radiology*, **2016**, 26, 4238-4248		17
224	Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. *Radiology*, **2016**, 280, 905-15	20.5	26
223	White Paper on P4 Concepts for Pediatric Imaging. *Journal of the American College of Radiology*, **2016**, 13, 590-597.e2	3.5	5
222	Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. *Investigative Radiology*, **2016**, 51, 221-227	10.1	59
221	Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. *Nature Nanotechnology*, **2016**, 11, 986-994	28.7	847
220	Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. *Journal of Nuclear Medicine*, **2015**, 56, 274-86	8.9	75
219	Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. *Nanomedicine*, **2015**, 10, 993-1018	5.6	79
218	Reply to Dr. Vazquez et al. regarding current methods for reducing intussusception: external manual reduction with US assistance. *Pediatric Radiology*, **2015**, 45, 1262	2.8	
217	Current methods for reducing intussusception: survey results. *Pediatric Radiology*, **2015**, 45, 667-74	2.8	35
216	Imaging Tumor Necrosis with Ferumoxytol. *PLoS ONE*, **2015**, 10, e0142665	3.7	27
215	Magnetic resonance imaging of stem cell apoptosis in arthritic joints with a caspase activatable contrast agent. *ACS Nano*, **2015**, 9, 1150-60	16.7	61
214	Improved approach for chondrogenic differentiation of human induced pluripotent stem cells. *Stem Cell Reviews and Reports*, **2015**, 11, 242-53	6.4	75
213	Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. *Small*, **2014**, 10, 566-75, 417	11	112
212	ACR Committee on Pediatric Imaging Research. *Pediatric Radiology*, **2014**, 44, 1193-1194	2.8	2

211	Basic science research in pediatric radiology - how to empower the leading edge of our field. *Pediatric Radiology*, **2014**, 44, 935-9	2.8	
210	Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. *Lancet Oncology, The*, **2014**, 15, 275-85	21.7	114
209	(18)F-FDG PET/CT scans for children and adolescents - authors' reply. *Lancet Oncology, The*, **2014**, 15, e244	21.7	1
208	MR Imaging of Stem Cell Transplants in Arthritic Joints. *Journal of Stem Cell Research & Therapy*, **2014**, 4, 165	1	9
207	Successful Treatment with Temozolomide Combined with Chemoradiotherapy and Surgery of a Metastatic Undifferentiated Soft Tissue Sarcoma with Relapse in the Central Nervous System of a Young Adult. *Journal of Adolescent and Young Adult Oncology*, **2014**, 3, 100-103	2.2	
206	Comparison of Latino and non-Latino patients with Ewing sarcoma. *Pediatric Blood and Cancer*, **2014**, 61, 233-7	3	6
205	Pediatric Molecular Imaging **2014**, 571-595		
204	Role of diffusion-weighted imaging in differentiating benign and malignant pediatric abdominal tumors. *Pediatric Radiology*, **2013**, 43, 836-45	2.8	34
203	Magnetic Resonance Imaging of the Bone Marrow Contrast Media for Bone Marrow Imaging. *Medical Radiology*, **2013**, 355-365	0.2	
202	Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. *European Radiology*, **2013**, 23, 1271-80	8	20
201	Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses. *Contrast Media and Molecular Imaging*, **2013**, 8, 281-8	3.2	22
200	Magnetic resonance imaging and tracking of stem cells. *Methods in Molecular Biology*, **2013**, 1052, 167-76	1.4	12
199	Iron administration before stem cell harvest enables MR imaging tracking after transplantation. *Radiology*, **2013**, 269, 186-97	20.5	53
198	Enhancing in vivo survival of adipose-derived stromal cells through Bcl-2 overexpression using a minicircle vector. *Stem Cells Translational Medicine*, **2013**, 2, 690-702	6.9	26
197	Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. *Nanomedicine*, **2013**, 8, 1969-83	5.6	66
196	Engineering stem cells for treatment of osteochondral defects. *Skeletal Radiology*, **2012**, 41, 1-4	2.7	7
195	Differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT. *Radiology*, **2012**, 262, 613-22	20.5	38
194	High-resolution MR imaging of the orbit in patients with retinoblastoma. *Radiographics*, **2012**, 32, 1307-26	2.4	20

193	MR imaging features of gadofluorine-labeled matrix-associated stem cell implants in cartilage defects. *PLoS ONE*, **2012**, 7, e49971	3.7	8
192	MR imaging of tumor-associated macrophages. *OncoImmunology*, **2012**, 1, 507-509	7.2	27
191	Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. *Journal of Nuclear Medicine*, **2012**, 53, 1155-63	8.9	54
190	FDG PET/CT for the evaluation of normal thymus, lymphoma recurrence, and mediastinal lymphoma in pediatric patients. *Radiology*, **2012**, 264, 918-9; author reply 919-20	20.5	7
189	Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants. *Radiology*, **2012**, 264, 803-11	20.5	48
188	A photonic crystal cavity-optical fiber tip nanoparticle sensor for biomedical applications. *Applied Physics Letters*, **2012**, 100, 213702	3.4	23
187	Magnetic Resonance Imaging of Ferumoxide-Labeled Mesenchymal Stem Cells in Cartilage Defects: In Vitro and in Vivo Investigations. *Molecular Imaging*, **2012**, 11, 7290.2011.00040	3.7	30
186	Somatic differentiation and MR imaging of magnetically labeled human embryonic stem cells. *Cell Transplantation*, **2012**, 21, 2555-67	4	25
185	Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations. *Molecular Imaging*, **2012**, 11, 197-209	3.7	26
184	MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. *Clinical Cancer Research*, **2011**, 17, 5695-704	12.9	224
183	Labeling stem cells with ferumoxytol, an FDA-approved iron oxide nanoparticle. *Journal of Visualized Experiments*, **2011**, e3482	1.6	60
182	Labeling human mesenchymal stem cells with fluorescent contrast agents: the biological impact. *Molecular Imaging and Biology*, **2011**, 13, 3-9	3.8	25
181	Labeling human embryonic stem-cell-derived cardiomyocytes for tracking with MR imaging. *Pediatric Radiology*, **2011**, 41, 1384-92	2.8	13
180	A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. *Pediatric Blood and Cancer*, **2011**, 57, 275-82	3	34
179	Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. *Magnetic Resonance in Medicine*, **2011**, 65, 756-63	4.4	33
178	Optical imaging of rheumatoid arthritis. *International Journal of Clinical Rheumatology*, **2011**, 6, 67-75	1.5	29
177	NK-cell tracking using non-invasive imaging modalities **2010**, 653-664		
176	Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. *Radiology*, **2010**, 255, 527-35	20.5	113

175	Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. *Cancer Research*, **2010**, 70, 6109-13	10.1	30
174	MR signal characteristics of viable and apoptotic human mesenchymal stem cells in matrix-associated stem cell implants for treatment of osteoarthritis. *Investigative Radiology*, **2010**, 45, 634-40	10.1	32
173	Labeling Human Embryonic Stem Cell-Derived Cardiomyocytes with Indocyanine Green for Noninvasive Tracking with Optical Imaging: An FDA-Compatible Alternative to Firefly Luciferase. *Cell Transplantation*, **2010**, 19, 55-65	4	28
172	Uterine didelphys associated with obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome. *Radiology Case Reports*, **2010**, 5, 327	1	17
171	Implantation of ferumoxides labeled human mesenchymal stem cells in cartilage defects. *Journal of Visualized Experiments*, **2010**,	1.6	7
170	Accelerated stem cell labeling with ferucarbotran and protamine. *European Radiology*, **2010**, 20, 640-8	8	19
169	Ectopic ureter associated with uterine didelphys and obstructed hemivagina: preoperative diagnosis by MRI. *Pediatric Radiology*, **2010**, 40, 358-60	2.8	17
168	Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging. *Pediatric Radiology*, **2010**, 40, 1380-6	2.8	21
167	Radiological-pathological correlation of pleomorphic liposarcoma of the anterior mediastinum in a 17-year-old girl. *Pediatric Radiology*, **2010**, 40 Suppl 1, S68-70	2.8	57
166	Indocyanine green-enhanced imaging of antigen-induced arthritis with an integrated optical imaging/radiography system. *Arthritis and Rheumatism*, **2010**, 62, 2322-7		40
165	Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly luciferase. *Cell Transplantation*, **2010**, 19, 55-65	4	14
164	In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label. *Molecular Imaging*, **2010**, 9, 278-90	3.7	16
163	In Vivo Magnetic Resonance Imaging and Optical Imaging Comparison of Viable and Nonviable Mesenchymal Stem Cells with a Bifunctional Label. *Molecular Imaging*, **2010**, 9, 7290.2010.00029	3.7	28
162	Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. *Journal of Clinical Oncology*, **2009**, 27, 1290-6	2.2	66
161	New perspectives on bone marrow contrast agents and molecular imaging. *Seminars in Musculoskeletal Radiology*, **2009**, 13, 145-56	1.8	11
160	The influence of ferucarbotran on the chondrogenesis of human mesenchymal stem cells. *Contrast Media and Molecular Imaging*, **2009**, 4, 165-73	3.2	62
159	Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: discrimination of viable from lysed cells. *Magnetic Resonance in Medicine*, **2009**, 62, 325-32	4.4	47
158	Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. *Pediatric Radiology*, **2009**, 39, 1194-202	2.8	19

157	Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 23-36	8.8	117
156	Pediatric liver tumors--a pictorial review. *European Radiology*, **2009**, 19, 209-19	8	39
155	An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis. *Optics Express*, **2009**, 17, 24403-13	3.3	17
154	Optical imaging of the peri-tumoral inflammatory response in breast cancer. *Journal of Translational Medicine*, **2009**, 7, 94	8.5	5
153	MR Imaging of Pediatric Arthritis. *Radiologic Clinics of North America*, **2009**, 47, 939-955	2.3	2
152	MR imaging of pediatric arthritis. *Magnetic Resonance Imaging Clinics of North America*, **2009**, 17, 451-67, vi	1.6	26
151	Optical Imaging of Cellular Immunotherapy against Prostate Cancer. *Molecular Imaging*, **2009**, 8, 7290.2009.00002	3.7	36
150	Multiple Scalp Lesions in a Patient with Keratitis, Ichthyosis and Deafness Syndrome Mimicking Metastatic Squamous Cell Carcinoma on 18F-FDG PET/CT. *Radiology Case Reports*, **2009**, 4, 218	1	1
149	Optical imaging of cellular immunotherapy against prostate cancer. *Molecular Imaging*, **2009**, 8, 15-26	3.7	36
148	Detection of postoperative granulation tissue with an ICG-enhanced integrated OI-/X-ray System. *Journal of Translational Medicine*, **2008**, 6, 73	8.5	11
147	Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. *Nuclear Medicine and Biology*, **2008**, 35, 579-88	2.1	60
146	Imaging characteristics of DHOG, a hepatobiliary contrast agent for preclinical microCT in mice. *Academic Radiology*, **2008**, 15, 342-9	4.3	23
145	Labeling hESCs and hMSCs with iron oxide nanoparticles for non-invasive in vivo tracking with MR imaging. *Journal of Visualized Experiments*, **2008**,	1.6	13
144	MR imaging of ovarian tumors using folate-receptor-targeted contrast agents. *Pediatric Radiology*, **2008**, 38, 529-37	2.8	36
143	Receptor imaging of pediatric tumors: clinical practice and new developments. *Pediatric Radiology*, **2008**, 38, 1154-61	2.8	4
142	Improved fluorescence of indocyanine green in vitro and in vivo after simple cooling procedures. *Contrast Media and Molecular Imaging*, **2008**, 3, 191-7	3.2	6
141	Labeling stem cells with fluorescent dyes for non-invasive detection with optical imaging. *Journal of Visualized Experiments*, **2008**,	1.6	20
140	Cell tracking with optical imaging. *European Radiology*, **2008**, 18, 2021-32	8	155

139	MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent. *Contrast Media and Molecular Imaging*, **2007**, 2, 72-81	3.2	21
138	Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 858-64	4	25
137	MR imaging of therapy-induced changes of bone marrow. *European Radiology*, **2007**, 17, 743-61	8	113
136	Cell labeling with the positive MR contrast agent Gadofluorine M. *European Radiology*, **2007**, 17, 1226-34	8	42
135	Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 998-1006	8.8	34
134	MRI of arthritis: comparison of ultrasmall superparamagnetic iron oxide vs. Gd-DTPA. *Journal of Magnetic Resonance Imaging*, **2006**, 23, 720-7	5.6	39
133	Imaging of tumor angiogenesis: current approaches and future prospects. *Current Pharmaceutical Design*, **2006**, 12, 2661-72	3.3	41
132	Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. *Investigative Radiology*, **2006**, 41, 45-51	10.1	91
131	T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. *European Radiology*, **2006**, 16, 738-45	8	148
130	Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas. *European Radiology*, **2006**, 16, 598-607	8	32
129	Comparison of iron oxide labeling properties of hematopoietic progenitor cells from umbilical cord blood and from peripheral blood for subsequent in vivo tracking in a xenotransplant mouse model XXX. *Academic Radiology*, **2005**, 12, 502-10	4.3	43
128	Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research. *Academic Radiology*, **2005**, 12, 1190-7	4.3	23
127	Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. *Radiology*, **2005**, 234, 197-205	20.5	162
126	The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. *Investigative Radiology*, **2005**, 40, 349-54	10.1	29
125	In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. *European Radiology*, **2005**, 15, 4-13	8	154
124	Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. *European Radiology*, **2005**, 15, 895-903	8	30
123	Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. *Journal of Magnetic Resonance Imaging*, **2005**, 22, 549-58	5.6	5
122	Optimization of gadodiamide concentration for MR arthrography at 3 T. *American Journal of Roentgenology*, **2005**, 184, 1754-61	5.4	29

121	Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. *European Radiology*, **2004**, 14, 1851-8	8	205
120	Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. *Microcirculation*, **2004**, 11, 387-96	2.9	28
119	Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2004**, 31, 1312-21	8.8	76
118	Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. *Radiology*, **2003**, 229, 885-92	20.5	68
117	Targeting of hematopoietic progenitor cells with MR contrast agents. *Radiology*, **2003**, 228, 760-7	20.5	179
116	Macromolecular contrast agents for MR mammography: current status. *European Radiology*, **2003**, 13, 354-65	8	73
115	Highly efficient paramagnetic labelling of embryonic and neuronal stem cells. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 1038-44	8.8	67
114	MR Imaging of Hepatic Metastases. *Imaging Decisions (Berlin, Germany)*, **2003**, 7, 19-28		1
113	Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. *Academic Radiology*, **2003**, 10, 1237-46	4.3	27
112	Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent Gadophrin-3. *Academic Radiology*, **2003**, 10, 484-90	4.3	42
111	Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. *European Radiology*, **2002**, 12, 1557-66	8	73
110	FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. *Annals of Oncology*, **2002**, 13, 157-60	10.3	142
109	Comparison between gadopentetate and feruglose (Clariscan)-enhanced MR-mammography: preliminary clinical experience. *Academic Radiology*, **2002**, 9 Suppl 2, S343-7	4.3	5
108	Carboxymethyldextran-A2-Gd-DOTA enhancement patterns in the abdomen and pelvis in an animal model. *European Radiology*, **2001**, 11, 1276-84	8	8
107	Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. *American Journal of Roentgenology*, **2001**, 177, 229-36	5.4	362
106	FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. *Annals of Oncology*, **2001**, 12, 479-86	10.3	163
105	Quantitative gadopentetate-enhanced MRI of breast tumors: testing of different analytic methods. *Magnetic Resonance in Medicine*, **2000**, 44, 915-24	4.4	36
104	Assessing permeability alterations of the blood-bone marrow barrier due to total body irradiation: in vivo quantification with contrast enhanced magnetic resonance imaging. *Bone Marrow Transplantation*, **2000**, 25, 71-8	4.4	23

103	FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2000**, 27, 1305-11		229
102	Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. *American Journal of Roentgenology*, **2000**, 175, 1111-20	5.4	83
101	Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. *Radiology*, **2000**, 215, 727-36	20.5	173
100	Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. *Academic Radiology*, **2000**, 7, 934-44	4.3	25
99	CT of metal implants: reduction of artifacts using an extended CT scale technique. *Journal of Computer Assisted Tomography*, **2000**, 24, 165-72	2.2	81
98	Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI. *Journal of Magnetic Resonance Imaging*, **1999**, 9, 643-52	5.6	44
97	Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. *Magnetic Resonance in Medicine*, **1998**, 40, 537-43	4.4	76
96	Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. *Pediatric Radiology*, **1998**, 28, 67-78	2.8	69
95	High resolution MRI of small joints: impact of spatial resolution on diagnostic performance and SNR. *Magnetic Resonance Imaging*, **1998**, 16, 147-55	3.3	66
94	Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. *American Journal of Roentgenology*, **1998**, 171, 941-9	5.4	223
93	Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. *Academic Radiology*, **1998**, 5 Suppl 1, S2-5	4.3	19
92	Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. *European Radiology*, **1997**, 7, 275-80	8	147
91	Evaluation of myelination and myelination disorders with turbo inversion recovery magnetic resonance imaging. *European Radiology*, **1997**, 7, 1478-84	8	5
90	Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. *Radiology*, **1996**, 199, 177-83	20.5	274
89	Clinical results with Resovist: a phase 2 clinical trial. *Radiology*, **1995**, 195, 489-96	20.5	158
88	Chest wall sarcoma370-373		
87	Stem Cell Tracking65-75		
86	Fibromuscular dysplasia158-161		

[-]